Castle Biosciences, Inc. (CSTL) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 11 Buy.
The consensus price target is $49.80 (low: $47.00, high: $52.00), representing an upside of 104.3% from the current price $24.37.
Analysts estimate Earnings Per Share (EPS) of $0.39 and revenue of $0.33B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.66 vs est $0.39 (beat +68.4%). 2025: actual $-0.83 vs est $-1.04 (beat +20.1%). Analyst accuracy: 67%.
CSTL Stock — 12-Month Price Forecast
$49.80
▲ +104.35% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Castle Biosciences, Inc., the average price target is $49.80, with a high forecast of $52.00, and a low forecast of $47.00.
The average price target represents a +104.35% change from the last price of $24.37.
Highest Price Target
$52.00
Average Price Target
$49.80
Lowest Price Target
$47.00
CSTL Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Castle Biosciences, Inc. in the past 3 months
EPS Estimates — CSTL
67%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.66
vs Est $0.39
▲ 40.6% off
2025
Actual –$0.83
vs Est –$1.04
▲ 25.1% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — CSTL
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.332B
vs Est $0.327B
▲ 1.4% off
2025
Actual $0.344B
vs Est $0.336B
▲ 2.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
